COSCIENS Biopharma (CSCIF) Income Statement
COSCIENS Biopharma Income Statement
Last quarter (Q2 2026), COSCIENS Biopharma's total revenue was $3.06M, an increase of 9.99% from the same quarter last year. In Q2, COSCIENS Biopharma's net income was $-196.79K. See COSCIENS Biopharma’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 7.63M | $ 9.59M | $ 4.50M | $ 14.57M | $ 5.26M | |
| $ 2.69M | $ 4.73M | $ 4.28M | $ 8.56M | $ 5.17M | |
| $ 13.32M | $ 18.75M | $ 22.28M | $ 28.21M | $ 13.84M | |
| Depreciation and Amortization | $ 1.21M | $ 1.61M | $ 1.44M | $ 1.47M | $ 146.66K |
| $ -9.41M | $ -13.49M | $ -16.57M | $ -13.91M | $ 2.85M | |
| $ -10.62M | $ -14.02M | $ -18.01M | $ -15.38M | $ -8.67M | |
| $ 94.63K | $ -1.20M | $ 1.46M | $ -7.35M | $ 194.00K | |
| $ -10.53M | $ -15.22M | $ -16.55M | $ -22.73M | $ -8.48M | |
| $ -10.54M | $ -15.31M | $ -3.55M | $ 3.24M | $ 2.64M | |
| Per Share Metrics | |||||
| Basic EPS | $ -29.97 | $ -17.79 | $ -5.67 | $ 5.61 | $ 3.99 |
| Diluted EPS | $ -29.97 | $ -17.79 | $ -5.67 | $ 5.58 | $ 3.99 |
| Weighted Average Shares Outstanding | 351.70K | 860.44K | 539.54K | 539.54K | 510.78K |
| Weighted Average Shares Outstanding (Diluted) | 351.70K | 860.44K | 539.54K | 539.54K | 510.78K |
Currency in USD
